Pharmacologic Agents for Treatment of Type 2 Diabetes

Similar documents
What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018

Oral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

What s New in Diabetes Medications. Jena Torpin, PharmD

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Diabetes Medications: Oral Anti-Hyperglycemic Medications

Non-Insulin Diabetes Medications Summary

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents

Diabetes Treatment Guidelines

DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical

What s New in Diabetes Treatment. Disclosures

Oral and Injectable Non-insulin Antihyperglycemic Agents

Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

I. General Considerations

Table 1. Antihyperglycemic agents for use in type 2 diabetes

Physician Drug Reference Chart for Diabetes Antidiabetic Medications

DM Fundamentals Class 4 Meds for Type 2

Diabetes Mellitus II CPG

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism

Type 2 Diabetes Mellitus hypoglycaemic agents

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

New Therapies for Diabetes

1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime

Pharmacology. Kacy Aderhold, MSN, APRN-CNS, CMSRN

Date of Review: September 2016 Date of Last Review: September 2015

Drug Class Review Newer Diabetes Medications and Combinations

Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol

6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE

STEP THERAPY CRITERIA

The Death of Sulfonylureas? A Review of New Diabetes Medications

Oral and Injectable Medication Options for Diabetes Treatment

DM Fundamentals Class 4 Meds for Type 2

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix

Diabetes Management: A diagnostic perspective

Diabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Advanced Practice Education Associates. Endocrine

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

Managing Complex Diabetes Cases: Medication Update. Celia Levesque MSN, RN, CNS-BC, CDE, BC-ADM

How can we improve outcomes in Type 2 diabetes?

Very Practical Tips for Managing Type 2 Diabetes

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

Newer Drugs in the Management of Type 2 Diabetes Mellitus

Antidiabetic Agents CHAPTER BIGUANIDES

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Type II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS

2/17/2016. Objectives. Define. Hey Sugar! DMII Management in Hospice Care

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol

Clinical Practice Guidelines

Collaborative Practice Agreement

What s New on the Horizon: Diabetes Medication Update

2/9/2016. The Evolving Armamentarium for Type 2 Diabetes: Incorporating New Classes in the Treatment of Our Patients. Objectives: Pharmacists

Glucose Control drug treatments

CURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013

Ertugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy

What You Should Know About Diabetes. Laura Bingell RN Transition Center Nurse for MFP (607)

Diabetes 2016: Strategies for achieving optimal diabetes control

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol

2018 Diabetes Summit Managing Diabetes: An Art and a Science

3. Cardiovascular Disease?

What s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA

Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

Multiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014

How to Fight Diabetes and Win. Diabetes. Medications

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function

Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18

Rebecca Newberry APRN MS CDE

Initiating Injectable Therapy in Type 2 Diabetes

Welcome to the PHASE Learning Community! October 31, 2018

ORAL AGENTS OLD & NEW FOR THE MANAGEMENT OF T2DM

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM

Diabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System

Preventing Heart Attacks and Strokes Every Day (PHASE) RCHC Medication Titration Algorithm

CURRENT ISSUES IN DIABETES MANAGEMENT

Supplementary Online Content

Diabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System

Drug Class Monograph

Clinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018

Management of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test

DIABETES UPDATE 2018

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

Drugs used in Diabetes. Dr Andrew Smith

Management of Type 2 Diabetes: Should We Change Our Algorithm?

Management of Diabetes Mellitus: A Primary Care Perspective

Disclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017

Remote attendees, please mute your phones as a courtesy thank you!

Wayne Gravois, MD August 6, 2017

Treatment Options for Diabetes: An Update

Diabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider:

Transcription:

Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide 1 1 2.5 20 mg glipizide er 1 1 5 20 mg glipizide / 1 1 glyburide** glyburide** / 2.5 / 500 mg BID 1.25 20 mg 1.25 / 250 mg QD BID Nausea/ vomiting, GI upset, metallic taste, diarrhea, flatulence, lactic acidosis (rare) Nausea/ vomiting, GI upset, diarrhea, flatulence, lactic acidosis Dizziness, headache, hypoglycemia, nausea, weight gain Rash, diarrhea, dizziness, headache, diarrhea, hypoglycemia, nausea, weight gain Asthenia, headache, dizziness, rash, nausea, hypoglycemia, weight gain Rash, diarrhea, dizziness, headache, nausea, flatulence, hypoglycemia, lactic acidosis Rash, heartburn, hypoglycemia, nausea, hypoglycemia, weight gain Rash, heartburn, hypoglycemia, nausea, vomiting, lactic acidosis, flatulence

Medication Thiazolidinediones & Thiazolidinedione Combination Agents 15 45 mg pioglitazone 1 1 15 / 500 mg pioglitazone / 2 2 45 / 1500mg pioglitazone / glimepiride 2 [QL] 2 [QL] Alpha-Glucosidase Inhibitor acarbose 2 2 Meglitinides 15 / 500 mg 45 / 2550 mg 25 100 mg TID Administered at the start of each meal to decrease postprandial glucose peaks nateglinide 2 2 60 120 mg TID before meals repaglinide 2 2 0.5 4 mg TID before meals DPPIs (Dipeptidyl Peptidase-4 Inhibitors) JANUVIA (sitagliptin) 3 3 100 mg JANUMET, JANUMET XR (sitagliptin / 3 3 100 / 2000 mg Anemia, edema, weight gain, headache, myalgia, bone fracture, heart failure Rash, diarrhea, dizziness, headache, nausea, flatulence, hypoglycemia, lactic acidosis Anemia, edema, weight gain, headache, myalgia, dizziness, hypoglycemia, nausea Abdominal pain, diarrhea, flatulence, elevated serum transaminases Dizziness, arthralgia, diarrhea, hypoglycemia, weight gain, increased uric acid Hypoglycemia, arthralgia, diarrhea, weight gain Abdominal pain, diarrhea, headache, nasopharyngitis, nausea, URI, Abdominal pain, diarrhea, headache, nasopharyngitis, nausea, flatulence, lactic acidosis,

Medication KOMBIGLYZE Individualize XR 3 3 dose; 5 / 2000 (saxagliptin / mg max ONGLYZA (saxagliptin) 3 3 2.5 5 mg TRADJENTA (linagliptin) 5 mg Insulins Vial Pen Vial Pen HUMALOG HUMALOG MIX 50/50, 75/25 HUMULIN 70/30 HUMULIN N HUMULIN R 3-3 - HUMULIN R U-500 LANTUS (insulin glargine) LEVEMIR (insulin detemir) Patient specific dosing applies Nausea/ vomiting, GI upset, asthenia, diarrhea, flatulence, lactic acidosis, Abdominal pain, diarrhea, URI,, nausea, hypoglycemia Nasopharyngitis, diarrhea, cough, back pain, arthralgia, URI, headache Hypoglycemia, injection site reaction, lipodystrophy, hypokalemia NOVOLIN & NOVOLOG TOUJEO - 3-3

Medication GLP-1 Agonist (Glucagon-Like-Peptide-1) BYDUREON 2 mg SC (exenatide er) weekly BYETTA 5 10 mcg SC (exenatide) BID OZEMPIC 0.5 1 mg (semaglutide) weekly VICTOZA 0.6 mg 1.8mg (liraglutide) SC Amylinomimetic 60 mcg 120 SYMLIN PEN 3 [PA] 5 [PA] mcg SC prior to (pramlintide) main meals SGLT2 Inhibitor (Sodium-Glucose Cotransporter 2) FARXIGA 5 10 mg (dapagliflozin) XIGDUO XR (dapagliflozin/ INVOKANA (canagliflozin) INVOKAMET (canagliflozin/ INVOKAMET XR (canagliflozin/ 3 [ST] 3 [ST] 5 / 500 10 / 2000 mg 100 300 mg 50 / 500 150 / 1000 mg BID 100 / 1000 300 / 2000 mg Nausea, anorexia, dizziness, fatigue Genital mycotic infections, nasopharyngitis, UTI, back pain, increased urination, nausea Low vitamin-b12, diarrhea, headache, UTI, genital mycotic infection, nasopharyngitis Genital mycotic infections, UTI, thirst, increased urination, nausea Abdominal discomfort, constipation, diarrhea, flatulence, increased thirst, indigestion, N/V, asthenia, headache, UTI, polyuria pruritis Abdominal discomfort, constipation, diarrhea, flatulence, increased thirst, indigestion, N/V, asthenia, headache, UTI, polyuria pruritis Brand-name drugs are capitalized and generic drugs are listed in the lower-case italics. = Non-formulary [PA] = Prior Authorization [QL] = Quantity Limit [ST] = Step Therapy * 2009 AACE/ACE Consensus Statement ** High Risk Medication

Diabetes Guidelines References SCAN Health Plan Diabetes Guidelines adapted from: American Diabetes Association; Standards of Medical Care in Diabetes-: Diabetes Care January vol. 41 no. Supplement 1 S1-S159 http://care.diabetesjournals.org/content/diacare/suppl/2017/12/08/41.supplement_1.dc1/d C_41_S1_Combined.pdf Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm 2017 Executive Summary. Endocrine Practice. (2017, Feb). 23(2). 207-238. Drug Facts & Comparisons. (, Sept). Retrieved from www.online.factsandcomparisons.com. W olters Kluwer Health: Deventer, TheNetherlands. Epocrates Online (, Sept). Retrieved from: http://online.epocrates.com. Epocrates, Inc.: San Mateo, California. Reuben, D. B., Herr, K. A., Pacala, J. T., Pollock, B. G., Potter, J. F., & Semla, T. P. (2015). Geriatrics at your fingertips. 17th ed. (Based on AGS Guidelines.) Online Lexicomp (09/): 1100 Terex Road, Hudson, OH 44236